Skip to content

MRC

Experimental Medicine

Stage 2 round planned to open 8 October 2026, closing 24 February 2027; deferred round opens 15 April 2027, closing 1 September 2027

Last verified:

Is this grant right for you? Check your personalised match score. 30s, no email. See my matches →

The MRC Experimental Medicine programme funds human-centric mechanistic studies testing disease-mechanism hypotheses through direct interventions, compounds, biologics, vaccines, psychological, physiological or immune challenges. Applications must involve human participant recruitment and access to clinical infrastructure, open to UK-based researchers including a New Investigator Award track. The two-stage process runs in parallel rounds across 2026-2027.

Details

Funder MRC
Application 2-stage: stage one application → invited stage two application
Eligible countries GB

Eligibility & scope

Funds human-centric mechanistic experimental medicine studies testing hypotheses about disease mechanisms using interventions (compounds, biologics, psychological, physiological, vaccines, immune challenges). Requires human participant recruitment with clinical infrastructure. New Investigator Award track available. Applications in English; UK institutions. No matched funding requirement beyond standard 20% FEC.

Who Should Apply

  • Researchers based at UK academic, NHS, or healthcare institutions with clinical research access
  • Investigators with a track record of human-participant mechanistic studies, or New Investigator Award-track applicants launching an independent experimental medicine line
  • Projects testing causal hypotheses about disease mechanisms using direct interventions
  • Teams with established clinical or patient-recruitment infrastructure

Key Dates

  • Stage 2 round deadline 24 February 2027 (stage 1 invitations issued autumn 2026)
  • Deferred round opens 15 April 2027, closing 1 September 2027
  • Two-stage evaluation: stage one application → shortlisted to stage two full application

Tips for Applicants

  • Clinical infrastructure and recruitment capacity are gating; demonstrate existing relationships with NHS trusts or patient cohorts.
  • The hypothesis must be testable via direct intervention in humans, observational or computational-only work does not fit this remit.
  • New Investigator Award track has different expectations; emphasise independence and originality of the mechanistic hypothesis separately from supervisor legacy.

Frequently Asked Questions

What types of interventions does the MRC Experimental Medicine programme fund?

The programme supports studies using compounds, biologics, vaccines, psychological interventions, physiological challenges, or immune challenges to test disease-mechanism hypotheses in human participants.

Who is eligible for the MRC Experimental Medicine programme?

Researchers based at UK academic, NHS or other recognised UK research institutions with access to clinical infrastructure for human participant recruitment.

What is the stage 2 deadline for the MRC Experimental Medicine programme in 2027?

Stage 2 closes 24 February 2027 for the main round; a deferred round opens 15 April 2027 and closes 1 September 2027.

Is there a New Investigator Award track for the MRC Experimental Medicine programme?

Yes, a New Investigator Award track is available alongside the main stream, with differentiated eligibility and expectations for early-stage researchers launching independent experimental medicine research.

mrcexperimental-medicinehuman-studiesmechanistic-researchclinical-infrastructureuk-onlydisease-mechanism

Summary generated by AI based on published grant information. Always verify details on the funder's website.

More from MRC

Browse all open grants →

Browse Related

Could Experimental Medicine be right for you?

See your personalised match score for this grant and others in 30 seconds. No signup needed to preview.

See my matches free →